BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 179137)

  • 1. [Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].
    Jungi WF; Senn HJ; Beckmann C; Flury R; Frei P; Holdener E
    Schweiz Med Wochenschr; 1975 Oct; 105(42):1365-9. PubMed ID: 179137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors.
    Felix W; Senn HJ
    Cancer Chemother Rep; 1975; 59(4):737-42. PubMed ID: 1100224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A phase II study of oral VP-16 in primary lung cancer].
    Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Etoposide. A new highly effective cytostatic agent in anaplastic small-cell bronchial carcinoma, other solid tumors and hemoblastoses].
    Goldhirsch A; Joss R; Cavalli F; Sonntag RW; Ryssel HJ; Brunner KW
    Dtsch Med Wochenschr; 1981 Aug; 106(35):1105-9. PubMed ID: 6266800
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experiences with VP-16 in combination with cyclophosphamide or adriamycin in the anaplastic, predominantly small cell bronchogenic carcinoma].
    Schmieder HA; Jungi WF; Mayr AC; Senn HJ
    Schweiz Med Wochenschr; 1979 Jun; 109(22):841-4. PubMed ID: 462156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
    Kado M; Oshima S; Matsui Y; Shimokata K; Hara K; Kanda T; Shima K; Takenaka S
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):116-21. PubMed ID: 3002282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report.
    Chard RL; Krivit W; Bleyer WA; Hammond D
    Cancer Treat Rep; 1979; 63(11-12):1755-9. PubMed ID: 294306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A phase II study of NK171 (etoposide)].
    Kimura K; Niitani H
    Gan To Kagaku Ryoho; 1985 Oct; 12(10):2011-7. PubMed ID: 2996442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy of non-small-cell bronchial cancer with a combination of Cis-diamminedichloroplatinum (II) and VP 16-213].
    Joss R; Goldhirsch A; Cavalli F; Weber W; Kaplan S; Obrecht JP; Sonntag R; Brunner KW
    Schweiz Med Wochenschr; 1981 Sep; 111(36):1331-4. PubMed ID: 7197802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of anaplastic carcinoma of the lung with VP 16-213].
    Sanz Ortíz J; Saiz García F
    Med Clin (Barc); 1982 Oct 16-31; 79(7):322-4. PubMed ID: 6294420
    [No Abstract]   [Full Text] [Related]  

  • 11. [A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].
    Konno K; Nagahama F; Nakai Y; Nakabayashi T; Hiraga Y; Takebe K; Tamura M; Oizumi K; Sato M; Ito T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):931-7. PubMed ID: 3008671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of oral etoposide in small cell carcinoma of the lung].
    Miyamoto H; Ito M; Araya Y; Takaoka K; Isobe H; Dosaka H; Kawakami Y; Shimizu T; Onodera S
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1244-7. PubMed ID: 6329103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.
    Cohen MH; Broder LE; Fossieck BE; Ihde DC; Minna JD
    Cancer Treat Rep; 1977; 61(3):489-90. PubMed ID: 194694
    [No Abstract]   [Full Text] [Related]  

  • 14. [Phase II study of VP-16 (capsule) in solid tumors. A cooperative study].
    Honma T; Ogawa M; Yoshida S; Meguro S; Hirano M; Hoshino A; Shirakawa S; Nakamura T; Fukuoka M; Toki H
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):309-13. PubMed ID: 2982332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.
    Cavalli F; Sonntag RW; Jungi F; Senn HJ; Brunner KW
    Cancer Treat Rep; 1978 Mar; 62(3):473-5. PubMed ID: 348319
    [No Abstract]   [Full Text] [Related]  

  • 16. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical trial of oral etoposide in the treatment of malignancies].
    Zhang X; Zhu H; Xu J
    Zhonghua Zhong Liu Za Zhi; 1995 Nov; 17(6):454-7. PubMed ID: 8698002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vepeside (VP-16-213) in the treatment of bronchopulmonary cancer (preliminary data)].
    Anastasatu C; Burnea D; Iancovici O; Avramescu D; Burnea-Cornetti R
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1987; 36(1):41-56. PubMed ID: 3033800
    [No Abstract]   [Full Text] [Related]  

  • 19. High-dose etoposide (VP-16) in small-cell lung cancer.
    Greco FA; Johnson DH; Hande KR; Porter LL; Hainsworth JD; Wolff SN
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):42-4. PubMed ID: 2983434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of a new form of an oral administration of VP-16-213.
    Lau ME; Hansen HH; Nissen NI; Pedersen H
    Cancer Treat Rep; 1979 Mar; 63(3):485-7. PubMed ID: 371801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.